SAFC will continue to produce the API for cancer drug, Cloretazine.
Vion Pharmaceuticals extended its manufacturing agreement with SAFC for its lead anticancer agent, Cloretazine®, to September 2009. SAFC will continue to manufacture Cloretazine active pharmaceutical ingredient (API).
In December 2006, Vion entered into a manufacturing agreement for Cloretazine finished drug product with Ben Venue Laboratories. Ben Venue will manufacture Cloretazine finished drug product using API manufactured by SAFC.
